Namenda neuropathic pain trial
Forest will initiate a new Phase II trial of Namenda (memantine) for neuropathic pain, with a possible NDA submission by 2006. A previous Phase III study failed to show overall statistical significance in primary endpoint of nocturnal pain, although there was improvement in weekly assessments. Namenda was approved for treatment of moderate to severe Alzheimer's disease Oct. 16 (1"The Pink Sheet" Oct. 20, 2003, p. 3)...
You may also be interested in...
Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.